NASDAQ · ACET
Adicet Bio, Inc.
Healthcare · Biotechnology
$6.83▲ 7.56% ($0.48)at close
After hours$6.77▼ 0.88%4:55 PM ET
Market cap
$63.85M
P/E
-0.60
EPS (TTM)
-$9.21
Next earnings
Nov 4, 2026
Valuation
Revenue & margin DCF
A cash-flow estimate wouldn't be reliable here
Need current revenue and shares outstanding to build the revenue-driven FCFF model.
Only 2 of the five annual revenue periods are available; growth uses the observed fiscal-year spans.
Data notes
Only 2 of the five annual revenue periods are available; growth uses the observed fiscal-year spans.
- 10-yr revenue CAGR
- —
- Ending operating margin
- —
- Discount rate
- —
USD · Price used $6.83 · Price Sep 29, 8:00 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
What changed
The stock fell 48.61% over the last year. Free cash flow grew 15.25% over the trailing twelve months.
What the market seems to be pricing
Visible fundamentals weakened far less than the stock price. The market appears to be discounting durability, risk, or trust rather than just the latest reported numbers.
What would invalidate this read
This read is wrong if revenue rolls over, margins compress again, or free cash flow keeps deteriorating. In that case the selloff would be catching up with weaker business quality rather than just a lower multiple.
Return analysis
Company profile
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases.
Market multiples
Stock splits
Every 16 shares became 1
Every 7 shares became 1
Profitability & growth
Analyst consensus
9
Buy
3
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Nov 4, 2026
Q3 FY26 · EPS est -$1.56 · Revenue est —
View
Institutional Sentiment
Adicet Bio, Inc. · ACET
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.